{"id":"W4411017560","doi":"10.1016/j.esmoop.2025.105120","title":"Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"National Cancer Institute; University of California, San Francisco; Eisai; Daiichi-Sankyo; Veracyte; Genentech; NSABP Foundation; Les Laboratories Pierre Fabre; Astex Pharmaceuticals; Regeneron Pharmaceuticals; Gilead Sciences; Amgen; Pfizer; Novartis Pharmaceuticals Corporation; AstraZeneca; Eli Lilly and Company; F. Hoffmann-La Roche; Seagen; Roche","keywords":"Palbociclib; Medicine; Oncology; Breast cancer; Quality of life (healthcare); Adjuvant; Randomized controlled trial; Internal medicine; Cancer; Adjuvant therapy; Endocrine system; Gynecology; Metastatic breast cancer; Hormone","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002393821,0.001059358,0.001435389,0.0003090856,0.0002506392,0.0008637423,0.0008441251,0.0006694008,0.004787225],"category_scores_gemma":[0.001492782,0.0003754295,0.001552484,0.0003461947,0.0007026691,0.000569158,0.0005481612,0.002592081,0.0003846769],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008101619,"about_ca_system_score_gemma":0.001065482,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000988659,"about_ca_topic_score_gemma":0.001835726,"domain_scores_codex":[0.9990205,0.0006523407,0.00004517312,0.0001094397,0.00008118019,0.00009143593],"domain_scores_gemma":[0.9991078,0.0001851668,0.0003372281,0.00004514657,0.0000363276,0.0002883673],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9759797,0.003553785,0.003295493,0.0002844612,0.0008321843,0.00001995278,0.00001846606,0.0004728967,0.001005396,0.00008602793,0.0007827246,0.01366893],"study_design_scores_gemma":[0.8882653,0.09603938,0.0125622,0.00004562905,0.000828782,0.00006502164,0.00002174408,0.0007831198,0.0003303259,0.0002063172,0.0008397539,0.00001233694],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909145,0.004382309,0.0002285747,0.0005709443,0.0002524998,0.001010019,0.0008951191,0.00003974227,0.001706243],"genre_scores_gemma":[0.9935024,0.001181688,0.0006304274,0.0004702109,0.0002572649,0.001708089,0.001070182,0.000005690822,0.001174038],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004787225,"threshold_uncertainty_score":0.01601487,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03120879118476509,"score_gpt":0.3602247273950173,"score_spread":0.3290159362102522,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}